Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK2 | O95069 | 1/20 | 1.00 |
| ▸ | TRPM2 | O94759 | 3/20 | 0.79 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.73 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.73 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.73 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.73 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 4/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366850 | 1.00 | KCNK2 (1.00) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL3366853 | 1.00 | KCNK2 (1.00) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL6787369 | 0.90 | KCNK2 (0.81) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL6787364 | 0.90 | KCNK2 (0.81) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL28947494 | 0.88 | TRPM2 (1.00) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL28947495 | 0.88 | TRPM2 (1.00) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL16438113 | 0.87 | KCNK2 (0.77) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL29050647 | 0.86 | CYSLTR2 (0.78) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL30218660 | 0.84 | CYSLTR2 (1.00) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 | |
| SCHEMBL1895053 | 0.84 | CYSLTR2 (1.00) | KCNK2TRPM2CYSLTR2CYSLTR1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049747-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | TRUSTEES OF TUFTS COLLEGE | 2025-02-13 | — | — | US | claimed |
| EP-4447955-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | Trustees of Tufts College (US) | 2024-10-23 | — | — | EP | claimed |
| CN-118286413-A | Method for regulating BCG vaccine to induce and train immunity | 上海市公共卫生临床中心 | 2024-07-05 | — | — | CN | claimed |
| WO-2023114868-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | TRUSTEES OF TUFTS COLLEGE (US) | 2023-06-22 | — | — | WO | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250049747-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | TRUSTEES OF TUFTS COLLEGE | 2025-02-13 | — | — | US | disclosed |
| WO-2024233348-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES BY TARGETING PHOSPHOLIPIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4447955-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | Trustees of Tufts College (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118286413-A | Method for regulating BCG vaccine to induce and train immunity | 上海市公共卫生临床中心 | 2024-07-05 | — | — | CN | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-116585306-A | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023114868-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | TRUSTEES OF TUFTS COLLEGE (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-109562098-B | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | disclosed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-10-20 | — | — | US | disclosed |
| EP-4045026-A1 | EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES | Ophirex, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | KCNK2 520/4885TRPM2 124/4885CYSLTR2 103/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | KCNK2 1515/4885TRPM2 588/4885CYSLTR2 139/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | KCNK2 953/4885TRPM2 862/4885CYSLTR2 76/4885 |
| US-20250049747-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | MTOR, KCNN1, HCN4 | KCNK2 327/4885TRPM2 328/4885CYSLTR2 3907/4885 |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | KCNK2 809/4885TRPM2 896/4885CYSLTR2 72/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | KCNK2 484/4885TRPM2 517/4885CYSLTR2 48/4885 |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | KCNK2 662/4885TRPM2 948/4885CYSLTR2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.